2 Figures That'll Tell Us if Valeant Pharmaceuticals' Business Is Improving
In recent years, a Valeant Pharmaceuticals (NYSE: VRX) quarterly earnings report was grounds to call out sick from work, bury yourself under the blankets, and pray you'd still have money left when the day was complete. However, things changed during the previous quarter.
Back in August, the embattled drugmaker wound up reporting organic growth from both of its core operating segments, Bausch & Lomb and Salix Pharmaceuticals, and it stuck by its full-year EBITDA forecast of $3.6 billion to $3.75 billion. While far from anything worth crowing over, it wasn't a bad report. That's the first time investors could say such a thing in about two years.
Image source: Getty Images.
Source: Fool.com
Bausch Health Companies Inc. Aktie
5,52 €
0,60 %
Derzeit ist die Community gegenüber der Bausch Health Companies Inc. Aktie mit 5 Buy-Einschätzungen und 0 Sell-Einschätzungen positiv gestimmt.
Das von der Community festgelegte Kursziel für Bausch Health Companies Inc. von 16 € würde den aktuellen Kurs von 5.52 € mehr als verdoppeln.
